MX2023003273A - Ligandos de nlrx1. - Google Patents
Ligandos de nlrx1.Info
- Publication number
- MX2023003273A MX2023003273A MX2023003273A MX2023003273A MX2023003273A MX 2023003273 A MX2023003273 A MX 2023003273A MX 2023003273 A MX2023003273 A MX 2023003273A MX 2023003273 A MX2023003273 A MX 2023003273A MX 2023003273 A MX2023003273 A MX 2023003273A
- Authority
- MX
- Mexico
- Prior art keywords
- diseases
- disease
- chronic
- inflammatory
- compounds
- Prior art date
Links
- 101150046293 Nlrx1 gene Proteins 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 101001109452 Homo sapiens NLR family member X1 Proteins 0.000 abstract 2
- 102100022697 NLR family member X1 Human genes 0.000 abstract 2
- 230000001684 chronic effect Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000002757 inflammatory effect Effects 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 230000003959 neuroinflammation Effects 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 208000020431 spinal cord injury Diseases 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Apparatus For Radiation Diagnosis (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La invención proporciona compuestos que se dirigen al dominio de oligomerización de unión a nucleótidos, vía X1 (NLRX1) que contiene repeticiones ricas en leucina. Los compuestos se pueden usar para tratar afecciones tales como enfermedades autoinmunes, enfermedades alérgicas, enfermedades crónicas y/o inflamatorias del sistema nervioso central, enfermedades respiratorias crónicas y/o inflamatorias, cáncer y enfermedades infecciosas. Las condiciones ejemplares incluyen esclerosis múltiple, asma, enfermedad de Alzheimer, enfermedad de Parkinson, neuroinflamación resultante de, por ejemplo, accidente cerebrovascular, lesión cerebral traumática o lesión de la médula espinal, enfermedad pulmonar obstructiva crónica, fibrosis pulmonar idiopática y enfermedad inflamatoria intestinal.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063081016P | 2020-09-21 | 2020-09-21 | |
| PCT/US2021/051068 WO2022061224A1 (en) | 2020-09-21 | 2021-09-20 | Nlrx1 ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023003273A true MX2023003273A (es) | 2023-04-26 |
Family
ID=80739968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023003273A MX2023003273A (es) | 2020-09-21 | 2021-09-20 | Ligandos de nlrx1. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11548885B2 (es) |
| EP (1) | EP4196475A1 (es) |
| JP (1) | JP2023542921A (es) |
| KR (1) | KR20230074174A (es) |
| CN (1) | CN116368133A (es) |
| AR (1) | AR123560A1 (es) |
| AU (1) | AU2021342568A1 (es) |
| BR (1) | BR112023005189A2 (es) |
| CA (1) | CA3192644A1 (es) |
| CL (1) | CL2023000803A1 (es) |
| IL (1) | IL301346A (es) |
| MX (1) | MX2023003273A (es) |
| WO (1) | WO2022061224A1 (es) |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2268399C (en) | 1996-10-31 | 2008-08-19 | Harbor Branch Oceanographic Institution, Inc. | Anti-neurogenic inflammatory compounds and compositions and methods of use thereof |
| CA2293400A1 (en) | 1997-06-13 | 1998-12-17 | Gerald Mcmahon | Novel heteroaryl compounds for the modulation of protein tyrosine enzyme related cellular signal transduction |
| JPH1180110A (ja) | 1997-09-02 | 1999-03-26 | Fuji Photo Film Co Ltd | ジアゾニウム塩および感熱記録材料 |
| JP4244251B2 (ja) | 1999-02-22 | 2009-03-25 | 富士フイルム株式会社 | ジアゾ化合物および感熱記録材料 |
| US6197488B1 (en) | 1999-07-21 | 2001-03-06 | Eastman Kodak Company | Color photographic element containing a coupler releasing derivative with at least three heteroatoms with specific hydrophobicity |
| AUPR201600A0 (en) | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
| AU2002217742B2 (en) | 2001-01-16 | 2008-02-21 | Astrazeneca Ab | Therapeutic heterocyclic compounds |
| AU2002305926A1 (en) | 2001-02-05 | 2002-10-08 | Exegenics Inc. | Cysteine protease inhibitors |
| PE20030008A1 (es) | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | Inhibidores duales de pde 7 y pde 4 |
| ATE530520T1 (de) | 2001-08-10 | 2011-11-15 | Shionogi & Co | Antivirales mittel |
| JP2005511581A (ja) | 2001-11-07 | 2005-04-28 | メルク エンド カムパニー インコーポレーテッド | 有糸分裂キネシン阻害剤 |
| BR0302965A (pt) | 2002-02-01 | 2005-02-09 | King Pharmaceuticals Res & Dev | Composto e método de tratar doenças mediadas por receptores de adenosina a2b |
| ATE440825T1 (de) | 2003-06-06 | 2009-09-15 | Vertex Pharma | Pyrimidin-derivate zur verwendung als modulatoren von atp-bindende kassette transportern |
| US8143285B2 (en) | 2005-09-06 | 2012-03-27 | Shionogi & Co., Ltd. | Indolecarboxylic acid derivative having PGD2 receptor antagonistic activity |
| JP5030961B2 (ja) | 2005-10-11 | 2012-09-19 | サーントゥル ナシオナル ドゥ ラ ルシェルシュ シャーンティフィク | 細胞のアポトーシスの検出および定量化用の化合物およびキット |
| NZ546477A (en) | 2006-04-07 | 2009-04-30 | Auckland Uniservices Ltd | 4-Alkylamino-2-(heterocyclic)quinazolines and their use in cancer therapy |
| WO2008153701A1 (en) | 2007-05-24 | 2008-12-18 | Schering Corporation | Compounds for inhibiting ksp kinesin activity |
| WO2009042294A2 (en) | 2007-08-10 | 2009-04-02 | Burnham Institute For Medical Research | Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof |
| WO2010127208A1 (en) | 2009-04-30 | 2010-11-04 | Forest Laboratories Holdings Limited | Inhibitors of acetyl-coa carboxylase |
| WO2012087938A1 (en) * | 2010-12-20 | 2012-06-28 | Glaxosmithkline Llc | Quinazolinone derivatives as antiviral agents |
| CN102838600A (zh) | 2011-06-24 | 2012-12-26 | 山东亨利医药科技有限责任公司 | 苯基喹唑啉类PI3Kδ抑制剂 |
| WO2014087165A1 (en) | 2012-12-06 | 2014-06-12 | University Of Bath | Tankyrase inhibitors |
| PH12019500143A1 (en) | 2013-08-23 | 2020-03-02 | Neupharma Inc | Certain chemical entities, compositions, and methods |
| CN109134434B (zh) | 2017-11-06 | 2021-02-19 | 北京大学深圳研究生院 | 喹啉或喹唑啉类化合物及其制备方法和应用 |
| US10487057B1 (en) * | 2018-07-05 | 2019-11-26 | Landos Biopharma, Inc. | NLRX1 ligands |
-
2021
- 2021-09-20 KR KR1020237012417A patent/KR20230074174A/ko unknown
- 2021-09-20 BR BR112023005189A patent/BR112023005189A2/pt unknown
- 2021-09-20 CN CN202180064577.7A patent/CN116368133A/zh active Pending
- 2021-09-20 MX MX2023003273A patent/MX2023003273A/es unknown
- 2021-09-20 IL IL301346A patent/IL301346A/en unknown
- 2021-09-20 JP JP2023518124A patent/JP2023542921A/ja active Pending
- 2021-09-20 US US17/479,337 patent/US11548885B2/en active Active
- 2021-09-20 CA CA3192644A patent/CA3192644A1/en active Pending
- 2021-09-20 EP EP21790019.0A patent/EP4196475A1/en active Pending
- 2021-09-20 AU AU2021342568A patent/AU2021342568A1/en active Pending
- 2021-09-20 WO PCT/US2021/051068 patent/WO2022061224A1/en active Application Filing
- 2021-09-21 AR ARP210102616A patent/AR123560A1/es unknown
-
2022
- 2022-12-20 US US18/085,293 patent/US20230128450A1/en active Pending
-
2023
- 2023-03-20 CL CL2023000803A patent/CL2023000803A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021342568A1 (en) | 2023-04-20 |
| US11548885B2 (en) | 2023-01-10 |
| IL301346A (en) | 2023-05-01 |
| AR123560A1 (es) | 2022-12-14 |
| US20220089586A1 (en) | 2022-03-24 |
| CN116368133A (zh) | 2023-06-30 |
| BR112023005189A2 (pt) | 2023-04-25 |
| CL2023000803A1 (es) | 2023-11-17 |
| CA3192644A1 (en) | 2022-03-24 |
| KR20230074174A (ko) | 2023-05-26 |
| US20230128450A1 (en) | 2023-04-27 |
| WO2022061224A1 (en) | 2022-03-24 |
| EP4196475A1 (en) | 2023-06-21 |
| JP2023542921A (ja) | 2023-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018013174A (es) | Isoquinolin-3-il-carboxamidas y preparacion y uso de las mismas. | |
| WO2018060732A3 (en) | Compositions and methods for treating seizure disorders | |
| PH12018502259A1 (en) | Isoquinolin-3-yl carboxamides and preparation and use thereof | |
| WO2020160193A3 (en) | Compounds and uses thereof | |
| TN2018000299A1 (en) | Heterocyclic compound. | |
| MX2018000929A (es) | Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-il carbamato y derivados de 1,1,1-trifluoro-4- hidroxibutan-2-il carbamato como inhibidores de magl. | |
| MX2021004492A (es) | Composiciones para el tratamiento de trastornos del snc. | |
| WO2017075338A3 (en) | Delivery of central nervous system targeting polynucleotides | |
| PH12016501600A1 (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
| MX2023009652A (es) | Inhibidores peptidicos de la acumulacion de alfa-sinucleina basados en estructuras. | |
| MX2021004582A (es) | Compuesto 2-azabiciclo hexano inhibidor de jak. | |
| AU2012277802A8 (en) | Novel inhibitor compounds of phosphodiesterase type 10A | |
| WO2016100162A3 (en) | 5,5-bicyclic oxazole orexin receptor antagonists | |
| EP4356969A3 (en) | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections | |
| WO2015108490A3 (en) | Heteroaryl alkyne derivatives and uses thereof | |
| MX2021002521A (es) | Dimetilaminoazetidinaminas como inhibidores de jak. | |
| PH12020552092A1 (en) | Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease | |
| EA201892008A1 (ru) | Соединения и способы лечения неврологических и сердечно-сосудистых состояний | |
| EA201990450A1 (ru) | Ингибиторы киназы, содержащей домен с двумя лейциновыми "застежками-молниями" (dlk), для лечения заболевания | |
| WO2018023072A3 (en) | Compounds and compositions and uses thereof | |
| MX2019004859A (es) | Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas. | |
| MY196791A (en) | New tetrahydropyrimidodiazepin and dihydropyridodiazepin compounds for treating pain and pain related conditions | |
| BR112017008103A2 (pt) | composto, composição farmacêutica, métodos para tratar uma doença e uma condição, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo e de um segundo agente ativo. | |
| TN2019000143A1 (en) | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | |
| EA200601607A1 (ru) | Сульфонамидные соединения для лечения нейродегенеративных расстройств |